Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05162846 · ClinicalTrials.gov registry record · NA
Michigan Genetic Hereditary Testing (MiGHT)
A NA study, sponsored by University of Michigan Rogel Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 831
- Enrollment target
NCT05162846: Completed NA study, sponsored by University of Michigan Rogel Cancer Center.
NCT05162846 is a NA study that has completed, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 831 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (41% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05162846, a NA study, has completed, sponsored by University of Michigan Rogel Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 831 participants
- Enrollment target
Study Summary
The primary purpose of this study is to compare three interventions, two experimental and one standard of care (usual care), to see if the experimental interventions will increase the likelihood of a participant obtaining guideline-concordant genetic testing. Eligible participants will be randomized (assigned) to one of the following interventions: 1) Virtual genetics navigator, a mobile-optimized website, designed by the investigators, that delivers tailored messages and content; 2) two motivational interviewing (MI) telephone calls delivered by trained genetics health coaches; or 3) usual care.
Primary Outcome
The primary outcome is completion of genetic testing (yes/no) at 6 months after randomization by patient self-report.
Interventions
- BEHAVIORAL Motivational interviewing (MI)
- OTHER Publicly available genetic testing resources
- BEHAVIORAL Virtual genetics navigator
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 831 participants |
| Start Date | 2022-04-21 |
| Est. Completion | 2025-11-21 |
| Phase | NA |
What the finished NCT05162846 record still lists
NCT05162846 is an interventional study that assigns participants to a tested intervention. The registered 831 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (41% lower).
The record links to 0 conditions, and to 3 interventions - of which Motivational interviewing (MI) is the first listed.
NCT05162846 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05162846 about?
NCT05162846 is a clinical study titled "Michigan Genetic Hereditary Testing (MiGHT)". The primary purpose of this study is to compare three interventions, two experimental and one standard of care (usual care), to see if the experimental interventions will increase the likelihood of a participant obtaining guideline-concordant genetic testing. Eligible participants will be randomized...
What is the current status of trial NCT05162846?
This trial is currently completed. It is a NA study. The enrollment target is 831 participants. The study started on 2022-04-21. Estimated completion is 2025-11-21.
What interventions are being tested in trial NCT05162846?
The interventions under investigation include: Motivational interviewing (MI) (BEHAVIORAL), Publicly available genetic testing resources (OTHER), Virtual genetics navigator (BEHAVIORAL).
Who is sponsoring clinical trial NCT05162846?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05162846's enrollment target sits among peer trials
831 134th of 2000 higher than 1,867 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06910553 · 832 participants
IBD Pregnancy Registry
- NCT07089706 · 832 participants · Phase 4
A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Variant-containing Formulations
- NCT05067283 · 830 participants · Phase 1
A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)
- NCT06592924 · 830 participants · Phase 3
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI